Navigation Links
Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance
Date:2/3/2009

As of As of 31-Dec-08 31-Dec-07 (Unaudited) (Audited) Cash and cash equivalents $11,170 $39,164 Short-term investments 45,499 29,196 Accounts receivable, net 8,807 5,089 Prepaid expenses and other current assets 4,782 3,105 Total current assets 70,258 76,554 Property and equipment, net 15,562 10,412 Restricted cash 500 500 Other assets 369 463 Total assets $86,689 $87,929 Accounts payable $1,898 $1,966 Accrued expenses and other current liabilities 11,473 7,616 Deferred revenue 3,797 1,008 Notes payable, short-term 1,814 2,687 Notes payable, long-term 225 2,039 Other liabilities 1,307 1,447 Stockholders' equity 66,175 71,166 Total liabilities and stockholders' equity $86,689 $87,929 The condensed consolidated balance sheet at December 31, 2007 has been derived from the audited consolidated financial statements at that date included in the Company's Form 10-K for the fiscal year ended December 31, 2007.
'/>"/>
SOURCE Genomic Health
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Enrichment of Genomic Loci for Targeted Sequencing Application Is Focus of 2009 AGBT Conference Workshop
2. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
3. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
4. Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum
5. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
6. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
7. Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
8. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
9. Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
10. Transgenomic Receives Accreditation From College of American Pathologists
11. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... BURLINGTON, Mass. , July 30, 2014 /PRNewswire/ ... surveyed pharmacy and medical directors in ... key drivers of biosimilar market penetration will be ... care organizations (MCOs) and the expected lower cost ... strategies for biosimilars that meet their pricing expectations ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Contributed by Jeff Wilson, and Andrew Segal, M.D., Genitrix, LLC, ... Introduction , ... recently become a popular choice as a reporter gene. GFP can be ... and to track the expression, localization, , and ...
... Helen Chun, Milhan Telatar and Richard A. Gatti,Department ... , Introduction ... (PTT) is a method used to screen large coding , ... gene responsible , for the autosomal ...
... Gita Ohlsson and Marianne Schwartz, Department of Clinical Genetics, , ... Denmark, , ... Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency , ... 21-hydroxylase. , In addition to deletions, approximately 20 ...
Cached Biology Technology:Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 2Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 3Measuring Intracellular Enhanced Green Fluorescent Protein With the VersaFluor Fluorometer 4Protein Truncation Tests Using the DCode System 2Protein Truncation Tests Using the DCode System 3Detection of Mutations in the CYP21 Gene Using the DCode System 2Detection of Mutations in the CYP21 Gene Using the DCode System 3Detection of Mutations in the CYP21 Gene Using the DCode System 4Detection of Mutations in the CYP21 Gene Using the DCode System 5
(Date:7/30/2014)... University Professor Steven Chown has been awarded the ... for Excellence in Antarctic Research. , SCAR, an ... high quality international scientific research in the Antarctic ... region in the Earth system. The organisation also ... Treaty System, responsible for governing the region. , ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
(Date:7/30/2014)... 30, 2014 The Nano-Bio Manufacturing Consortium ... Air Force Research Laboratory (AFRL), has awarded funding ... University to develop electronics and biometric ... $425,000 project, with contributions from the University of ... Inc. ( Endicott, N.Y. ), is ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide derived ... rat and mouse protein kinase C zeta ... rat and mouse PKCzeta protein. Recognizes ... not cross-react with PKCiota/lambda. Reactivity: Mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Biology Products: